Patent ID: 8088375

Claim:
A method of reducing binding of human VEGF to a human VEGFR2 (VEGF Receptor 2), comprising: contacting human VEGF with a monoclonal antibody that binds to said human VEGF and comprises: a) an antibody variable domain comprising: i. a heavy chain variable domain comprising a CDR1 region identical to amino acid residues 30-35 of SEQ ID NO: 4, a CDR2 region identical to amino acid residues 50-66 of SEQ ID NO: 4 and a CDR3 region identical to amino acid residues 98-109 of SEQ ID NO: 4; and ii. a light chain variable domain comprising a CDR1 region identical to amino acid residues 23-35 of SEQ ID NO: 43, a CDR2 region identical to amino acid residues 51-57 of SEQ ID NO: 43 and a CDR3 region identical to amino acid residues 90-101 of SEQ ID NO: 43; or b) a variant of said antibody variable domain that is otherwise identical to said antibody variable domain except for up to 8 amino acid substitutions in said CDR regions, wherein binding of the monoclonal antibody to said human VEGF reduces binding of said human VEGF to said VEGFR2 receptor.